Compared to Estimates, 10x Genomics (TXG) Q1 Earnings: A Look at Key Metrics

For the quarter ended March 2025, 10x Genomics (TXG) reported revenue of $154.88 million, up 9.8% over the same period last year. EPS came in at -$0.36, compared to -$0.50 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $133.25 million, representing a surprise of +16.24%. The company delivered an EPS surprise of +20.00%, with the consensus EPS estimate being -$0.45.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how 10x Genomics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenues- Consumables: $115.36 million compared to the $115.85 million average estimate based on two analysts. The reported number represents a change of +4.6% year over year. Revenues- Instruments: $14.82 million compared to the $17.30 million average estimate based on two analysts. The reported number represents a change of -41.8% year over year. Revenues- Instruments- Chromium: $5.91 million versus $6.46 million estimated by two analysts on average. Revenues- Services: $7.65 million compared to the $6.30 million average estimate based on two analysts. The reported number represents a change of +46.7% year over year. Revenues- Consumables- Chromium: $84.11 million versus the two-analyst average estimate of $82.93 million. Revenues- Consumables- Spatial: $31.25 million versus the two-analyst average estimate of $32.91 million. Revenues- Instruments- Spatial: $8.90 million versus $10.85 million estimated by two analysts on average. View all Key Company Metrics for 10x Genomics here>>>Shares of 10x Genomics have returned -4.2% over the past month versus the Zacks S&P 500 composite's +11.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.7 Best Stocks for the Next 30 DaysJust released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention. See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report 10x Genomics (TXG): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks